Spero Therapeutics (SPRO) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $7.8 million.
- Spero Therapeutics' Accumulated Expenses fell 4905.4% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year decrease of 4905.4%. This contributed to the annual value of $17.7 million for FY2024, which is 17030.65% up from last year.
- Latest data reveals that Spero Therapeutics reported Accumulated Expenses of $7.8 million as of Q3 2025, which was down 4905.4% from $6.7 million recorded in Q2 2025.
- Spero Therapeutics' Accumulated Expenses' 5-year high stood at $17.7 million during Q4 2024, with a 5-year trough of $5.4 million in Q1 2024.
- Over the past 5 years, Spero Therapeutics' median Accumulated Expenses value was $8.9 million (recorded in 2023), while the average stood at $9.5 million.
- In the last 5 years, Spero Therapeutics' Accumulated Expenses soared by 17030.65% in 2024 and then tumbled by 4905.4% in 2025.
- Over the past 5 years, Spero Therapeutics' Accumulated Expenses (Quarter) stood at $14.4 million in 2021, then plummeted by 37.47% to $9.0 million in 2022, then decreased by 26.93% to $6.6 million in 2023, then soared by 170.31% to $17.7 million in 2024, then crashed by 55.94% to $7.8 million in 2025.
- Its last three reported values are $7.8 million in Q3 2025, $6.7 million for Q2 2025, and $8.2 million during Q1 2025.